Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
32 results
  • Melanoma

21-441          Phase II

A First in Human, Multicenter, Phase 1/2, Open Label Study of XTX101 Monotherapy and XTX101 and Atezolizumab Combination Therapy in Patients with Advanced Solid Tumors

  • Melanoma

21-756          Phase II

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors

  • Lung Cancer, Lymphoma, Melanoma, Head and Neck Cancer

21-258          Phase II

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab

  • Bladder Cancer, Melanoma, Lung Cancer, Head and Neck Cancer

18-418          Phase III

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.

  • Melanoma

23-191          Phase I

A Phase 1 Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors

  • Pancreatic Cancer, Melanoma, Lung Cancer, Colorectal Cancer

21-184          Phase I

A Phase 1, First-in-Human Study of DCC-3116 as a Single Agent and in Combination with Trametinib in Patients with Advanced or Metastatic Solid Tumors with RAS or RAF Mutations

  • Head and Neck Cancer, Melanoma

23-589          Phase I

A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Cutaneous, Subcutaneous, Soft Tissue or Nodal Tumors

  • Melanoma, Lung Cancer, Endometrial Cancer, Breast Cancer, Bladder Cancer, Uterine Cancer, Ovarian Cancer

22-430          Phase II

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

  • Ovarian Cancer, Prostate Cancer, Melanoma, Colorectal Cancer, Breast Cancer, Lung Cancer

22-577          Phase II

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)

  • Melanoma

21-285          Phase I

A Phase 1/2, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination with Intravenous Checkpoint Blockade in Adults with Metastatic Uveal Melanoma

Showing 1 - 10 of 32 results